- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Chemosensitization/Potentiation Therapy, Docetaxel
- Radiation · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 686
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- cisplatin, paclitaxel, phenoxodiol
- Drug
- Lead sponsor
- MEI Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Carboplatin, GM-CSF (Sargramostim), Interferon Gamma
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer
- Interventions
- VS-6063, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Michael McHale
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 136
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
- Conditions
- Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
- Interventions
- Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis, Paclitaxel, pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
- Drug · Procedure · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ovarian Cancer
- Interventions
- Yoga
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 9
- States / cities
- Hinsdale, Illinois • Springfield, Illinois • Ames, Iowa + 6 more
- Conditions
- Ovarian Cancer, Primary Peritoneal Serous Cancer, Fallopian Tube Cancer
- Interventions
- bevacizumab
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Fallopian Tube Neoplasms, High Grade Ovarian Serous Adenocarcinoma, Stage I Ovarian Cancer, Stage II Ovarian Cancer, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
- Interventions
- Uterine lavage, or a wash of the womb, Blood sample, Pap smear
- Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • San Francisco, California • Annapolis, Maryland + 3 more
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Dalantercept, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 40
- States / cities
- Fort Collins, Colorado • Hartford, Connecticut • New Britain, Connecticut + 27 more
- Conditions
- Constipation, Bowel Obstruction, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
- Interventions
- Cisplatin, No treatment
- Drug · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 59
- States / cities
- Duarte, California • La Jolla, California • Newport Beach, California + 43 more
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 72
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- intravenous docetaxel with intraperitoneal oxaliplatin, intravenous oxaliplatin with intraperitoneal docetaxel
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Papillary Serous Mullerian Tumor, Clear Cell Mullerian Tumor
- Interventions
- bevacizumab, erlotinib, paclitaxel, carboplatin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, paclitaxel, Avelumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 998 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 146
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 70 more
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
- Interventions
- Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 890 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more
- Conditions
- Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer
- Interventions
- Vigil, Durvalumab
- Biological · Drug
- Lead sponsor
- Mary Crowley Medical Research Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Interventions
- ribociclib, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Ronald Buckanovich
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 8
- States / cities
- Ann Arbor, Michigan • Bethel Park, Pennsylvania • Greensburg, Pennsylvania + 4 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- chemotherapy, cisplatin, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
- Interventions
- Chemotherapy, Laparotomy, Minimally Invasive Surgery, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 13
- States / cities
- Miami, Florida • Weston, Florida • Boston, Massachusetts + 7 more
- Conditions
- High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Mirvetuximab soravtansine, Carboplatin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Fresno, California • Fullerton, California + 30 more
- Conditions
- Ovarian Cancer
- Interventions
- Niraparib, Bevacizumab
- Drug
- Lead sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts